Harish Chowdary Gorrepati/LinkedIn
Sep 1, 2026, 15:09
Harish Chowdary Gorrepati: The HALT Paradox After TAV
Harish Chowdary Gorrepati, Interventional Cardiologist at Sri Venkateswara Institute of Medical Sciences (SVIMS), Tirupati, Fellow at Heart Center UMC, shared a post on LinkedIn:
“NOTION-4 Trial | TAVR and Antithrombotic Therapy.
Short-term DOAC after TAVR significantly reduced HALT at 3 months (31.8 percent – 12.1 percent), but this benefit was not sustained at 12 months (32.2 percent versus 28.3 percent; P=0.54).
Importantly, bleeding/clinical events were numerically higher with the DOAC strategy.
Key message: Reducing leaflet thrombosis on CT does not necessarily translate into better clinical outcomes.
SAPT remains the preferred strategy for patients without another indication for oral anticoagulation.”
Stay updated with Hemostasis Today.
-
Oct 16, 2026, 17:06Troels Wienecke: Connecting Myeloproliferative Disease and Ischemic Stroke
-
Oct 16, 2026, 17:03Only 5 Days Left to Submit Your Research for EAHAD 2027
-
Oct 16, 2026, 16:48Abdul Rahman: Reticulocyte Count and Bone Marrow Activity
-
Oct 16, 2026, 16:44DOAC Adherence in Stroke Patients With Atrial Fibrillation – International Journal of Stroke
-
Oct 16, 2026, 16:22Shannon Farmer: Driving Patient Blood Management Forward in Australia and New Zealand
-
Oct 16, 2026, 16:01Obi Light Ogbonnia: The Greatest Reward Is Changing Lives, Not Winning Awards
-
Oct 16, 2026, 15:18Carmine Liberatore: Limited Accuracy of VTE Risk Scores in Multiple Myeloma
-
Oct 16, 2026, 14:55Alex Borstein and the Bleeding Phenotype of Hemophilia A Carriers
-
Oct 16, 2026, 13:59Aya Akmal Amin: Antiphospholipid Syndrome Management and Risk Stratification